PARP inhibitor becomes new treatment option for some men with advanced prostate cancer

(University of Chicago Medical Center) Results from an international clinical trial found that men with advanced prostate cancer who have mutated BRCA1/BRCA2 genes can be treated successfully with a targeted therapy known as rucaparib.